My bookmarksSign up free
Source

2010/180/: Commission Decision of 25 March 2010 on amending Decision 2008/911/EC establishing a list of herbal substances, preparations and combinations thereof for use in traditional herbal medicinal products (notified under document C(2010) 1867) (Text with EEA relevance)

2010/180/: Commission Decision of 25 March 2010 on amending Decision 2008/911/EC establishing a list of herbal substances, preparations and combinations thereof for use in traditional herbal medicinal products (notified under document C(2010) 1867) (Text with EEA relevance)

Decision 2008/911/EC · Decision · 3 articles

Data as of 2026-07-04 · Compiled from an official source version. Later amendments or repeals may not be reflected; the official text prevails. · Read the official text ↗

Article 1

Open ↗

Decision 2008/911/EC is amended as follows: 1. Articles 1 and 2 are replaced by the following: ‘Article 1 A list of herbal substances, preparations and combinations thereof for use in traditional herbal medicinal products is established in Annex I. Article 2 The indications, the specified strengths and the posology, the route of administration and any other information necessary for the safe use of the herbal substance as a traditional medicinal product relevant for the herbal substances listed in Annex I are set out in Annex II.’. 2. Annexes I and II are amended in accordance with the Annex to this Decision.

Supplementary provisions

ANNEXSupplementary provisions

Open ↗

ANNEX Annexes I and II to Decision 2008/911/EC are amended as follows: 1. in Annex I, the following substance is inserted after Foeniculum vulgare Miller subsp. vulgare var. dulce (Miller) Thellung (sweet fennel fruit): ‘ Mentha x piperita L.’; 2. in Annex II, the following is inserted after the entry relating to Foeniculum vulgare Miller subsp. vulgare var. dulce (Miller) Thellung, fructus: ‘ COMMUNITY LIST ENTRY ON MENTHA x PIPERITA L., AETHEROLEUM Scientific name of the plant Mentha x piperita L. Botanical family Lamiaceae (Labiatae) Herbal preparation(s) Peppermint oil : essential oil obtained by steam distillation from the fresh aerial parts of the flowering plant European Pharmacopoeia monograph reference Peppermint oil — Menthae piperitae aetheroleum (01/2008:0405) Indication(s) Herbal medicinal product traditionally used: 1. for the relief of symptoms in coughs and colds; 2. for the symptomatic relief of localised muscle pain; 3. for the symptomatic relief of localised pruritic conditions in intact skin. The product is a traditional herbal medicinal product for use in specified indications exclusively based upon long-standing use. Type of tradition European Specified strength Indications 1, 2 and 3 Single dose Children between 4 to 10 years of age Semi-solid preparations 2-10 % Hydroethanolic preparations 2-4 % Children between 10 to 12 years of age, adolescents between 12 to 16 years of age Semi-solid preparations 5-15 % Hydroethanolic preparations 3-6 % Adolescents over 16 years of age, adults Semi-solid and oily preparations 5-20 % In aqueous-ethanol preparations 5-10 % In nasal ointments 1-5 % essential oil. Specified posology Up to three times daily The use in children under 2 years of age is contraindicated (see “Contraindications”). The use is not recommended in children between 2 to 4 years of age (see “Special warnings and precautions for use”). Route of administration Cutaneous and transdermal. Duration of use or any restrictions on the duration of use Indication 1 Not to be used for more than 2 weeks. Indications 2 and 3 It is not recommended to use the medicinal product continuously for more than 3 months. If the symptoms persist during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted. Any other information necessary for the safe use Contraindications Children under 2 years of age, because menthol can induce reflex apnoea and laryngospasm. Children with history of seizures (febrile or not). Hypersensitivity to peppermint oil or menthol. Special warnings and precautions for use Eye contact with unwashed hands after the application of peppermint oil may potentially cause irritation. Peppermint oil should not be applied on broken or irritated skin. The use is not recommended in children between 2 to 4 years of age, as there is no sufficient experience available. Interactions with other medicinal products and other forms of interaction None reported. Pregnancy and lactation In the absence of sufficient data, the use during pregnancy and lactation is not recommended. Effects on ability to drive and use machines No studies on the effect on the ability to drive and use machines have been performed. Undesirable effects Hypersensitivity reactions such as skin rash, contact dermatitis, and eye irritation have been reported. These reactions are most of the time mild and transient. The frequency is not known. Irritation of the skin and mucosa of the nose is possible, after local application. The frequency is not known. If other adverse reactions not mentioned above occur, a doctor or a qualified health care practitioner should be consulted. Overdose No case of overdose has been reported.’

Other acts of the same type
Commission Implementing Decision (EU) 2026/2216 of 28 September 2026 amending Implementing Decision (EU) 2026/582 concerning certain emergency measures relating to foot and mouth disease in Cyprus (notified under document C(2026) 6959)Council Implementing Decision (EU) 2026/2221 of 28 September 2026 identifying European Defence Projects of Common Interest under Regulation (EU) 2025/2643 of the European Parliament and of the CouncilCouncil Decision (EU) 2026/2222 of 28 September 2026 appointing a member of the Court of AuditorsCouncil Decision (EU) 2026/2225 of 28 September 2026 appointing a member and an alternate member, proposed by the Republic of Estonia, of the Committee of the RegionsCouncil Decision (EU) 2026/2233 of 28 September 2026 on the position to be taken on behalf of the European Union on the amendments to the Annexes to the Agreement concerning the International Carriage of Dangerous Goods by Road (ADR) and to the Regulations annexed to the European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways (ADN)Council Decision (EU) 2026/2244 of 28 September 2026 appointing two European Prosecutors of the European Public Prosecutor’s OfficeCommission Implementing Decision (EU) 2026/2139 of 25 September 2026 laying down rules for the application of Directive (EU) 2016/797 of the European Parliament and of the Council as regards a request from Sweden not to apply the requirement to regarding step position for vehicle access and egress set out in Commission Regulation (EU) No 1300/2014 (notified under document C(2026) 6692)Commission Implementing Decision (EU) 2026/2141 of 25 September 2026 allowing the extension of the action taken by the Belgian Federal Public Service Health, Food Chain Safety and Environment permitting the making available on the market and use of the biocidal products Recrute Pro and Recrute HD in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the Council (notified under document C(2026) 6678)Commission Implementing Decision (EU) 2026/2142 of 25 September 2026 allowing Italy to authorise a biocidal product containing sulfuryl fluoride for the protection of cultural heritage (notified under document C(2026) 6676)Commission Implementing Decision (EU) 2026/2146 of 25 September 2026 allowing Poland to authorise biocidal products containing ethylene oxide for the protection of cultural heritage (notified under document C(2026) 6682)Commission Implementing Decision (EU) 2026/2150 of 25 September 2026 allowing Czechia to authorise biocidal products containing ethylene oxide for the protection of cultural heritage (notified under document C(2026) 6691)Commission Implementing Decision (EU) 2026/2151 of 25 September 2026 postponing the expiry date of the approval of folpet for use in biocidal products of product-type 9 in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the Council (notified under document C(2026) 6695)

Source: EUR-Lex (Publications Office of the EU), © European Union, reuse permitted under Commission Decision 2011/833/EU.

Contents

What to look at next